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ORIGINAL ARTICLE
Impact of on-site testing for maternal syphilis on treatment
delays, treatment rates, and perinatal mortality in rural
South Africa: a randomised controlled trial
L Myer, D Wilkinson, C Lombard, K Zuma, K Rotchford, S S Abdool Karim
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Sex Transm Infect 2003;79:208–213
Background: Syphilis remains a significant cause of preventable perinatal death in developing coun-
tries, with many women remaining untested and thus untreated. Syphilis testing in the clinic (on-site test-
ing) may be a useful strategy to overcome this. We studied the impact of on-site syphilis testing on
treatment delays and rates, and perinatal mortality.
Methods: We conducted a cluster randomised controlled trial among seven pairs of primary health-
care clinics in rural South Africa, comparing on-site testing complemented by laboratory confirmation
versus laboratory testing alone. Intervention clinics used the on-site test conducted by primary care
nurses, with results and treatment available within an hour. Control clinics sent blood samples to the
provincial laboratory, with results returned 2 weeks later.
Results: Of 7134 women seeking antenatal care with available test results, 793 (11.1%) tested posi-
tive for syphilis. Women at intervention clinics completed treatment 16 days sooner on average (95%
confidence interval: 11 to 21), though there was no significant difference in the proportion receiving
adequate treatment at intervention (64%) and control (69%) clinics. There was also no significant dif-
ference in the proportion experiencing perinatal loss (3.3% v 5.1%; adjusted risk difference: −0.9%;
95% CI −4.4 to 2.7).
Conclusions: Despite reducing treatment delays, the addition of on-site syphilis testing to existing
laboratory testing services did not lead to higher treatment rates or reduce perinatal mortality. However
on-site testing for syphilis may remain an important option for improving antenatal care in settings
where laboratory facilities are not available.
Syphilis remains a major cause of avoidable perinataldeath in many developing countries1–6 despite beingtreatable, and despite the World Health Organization’s
recommendations for testing all pregnant women as part of
routine antenatal care.7 Although access to a laboratory is
available in some settings, even in these circumstances a
minority of women with syphilis may be fully treated,8 and
syphilis attributable perinatal mortality persists.9
The limitations of laboratory based testing are largely the
result of delays in identifying and treating infected women.9
On-site testing,with nurses in primary care clinics conducting
syphilis tests, provides rapid results and allows treatment to
begin immediately for women testing positive. On-site testing
could be used in addition to laboratory testing as an interven-
tion to reduce delays to treatment, increase the proportion of
women adequately treated, and hence reduce perinatal
mortality.10–12 In addition, access to laboratory facilities does
not exist in many primary healthcare systems, leaving many
pregnant women untested and untreated. As it appears to be
feasible,10 13 sufficiently sensitive,12 14 and associated with
improved treatment,13 15 on-site testing could be a particularly
important strategy for such settings.
On-site testing has been implemented in demonstration
projects in Kenya,10 16 Zambia,17 and Mozambique.15 Despite
generally positive results from these observational studies, to
date no randomised controlled trials have been undertaken to
evaluate the effect of on-site testing on treatment and
pregnancy outcomes. Here we compare the impact of adding
on-site antenatal testing to existing laboratory testing
services on treatment delays, treatment rates, and perinatal
mortality.
METHODS
We conducted a cluster randomised controlled trial in the
rural Hlabisa health district in KwaZulu-Natal, South Africa.
The district has a population of approximately 220 000 served
by 14 primary care clinics and a district hospital. Antenatal
care is available 1 day each week at each clinic, and most
women (95%) attend antenatal clinics at least once before
delivery.18 The clinics in the district were divided into seven
pairs, matched on uptake of antenatal care services, antenatal
syphilis prevalence, and geographical similarities (for exam-
ple, proximity to main roads) (fig 1). Within each pair, one
clinic was randomised to receive the intervention of on-site
syphilis testing complemented by confirmation in the
reference laboratory, and the other to continue routine labora-
tory testing. An independent scientist randomised the clinics
through toss of a coin; allocation was unblinded.
Participants
At each clinic, all pregnant women making their first
antenatal visit answered a brief questionnaire to collect
demographic information and pregnancy history. Blood speci-
mens used in the study were taken during specimen collection
for routine antenatal screening. Participants were women
with a positive test for syphilis. All women testing positive for
syphilis were given standard partner notification cards.
Intervention procedures
In the intervention clinics the rapid plasma reagin test
(Macro-Vue RPR Card Test, Becton-Dickinson, USA) was per-
formed on site by nursing staff. Nurse training at intervention
clinics consisted of a 1 day workshop on the conduct of the
on-site test. This included information on the logistics of the
test, including specimen handling andmaintenance, as well as
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supervised practice in conducting the test and reading test
results. Continued monitoring of on-site test performance, as
well as refresher training for new clinic staff, was provided at
intervention clinics throughout the trial.
In the on-site test, cells were separated from plasma by
standing for 30 minutes, and serum was mixed with RPR
antigen using a battery powered rotator according to the
manufacturer’s instructions. Clinic staff reported results as
either positive or negative using colour photographs as a
reference standard.Women whose on-site test was reported as
positive received the first of three recommended weekly intra-
muscular injections of 2.4 mega units benzathine penicillin on
the same day.8 13 In addition, all samples from intervention
clinics were sent to the provincial reference laboratory for
routine RPR (quantitative) testing. Women who tested
negative in the on-site test were counselled to return 2 weeks
later to receive their laboratory results; if they tested positive
only in the laboratory, these women were given their first
penicillin injection when they returned. Women testing posi-
tive on site but negative in laboratory tests were still
considered RPR positive and were counselled to complete their
treatment.
Control procedures
The study procedures at control sites followed routine
antenatal care practices in the district. Blood specimens drawn
during the first antenatal visit in control clinics were sent to
the provincial reference laboratory and all women were coun-
selled to return 2 weeks later to receive their results. On
returning, women with a positive result were counselled on
the treatment regimen and received their first penicillin injec-
tion.
Follow up
After receiving the first treatment dose, all women who tested
RPR positive (in either on-site or laboratory test) were
counselled to return to the clinic for two follow up injections
at weekly intervals. Pregnancy outcome data were determined
from hospital and clinic records, or by home visits where nec-
essary.
Definitions
The primary outcome of the trial, perinatal death, was defined
as either stillbirth (born dead at or after 28 weeks’ gestation)
or early neonatal death (death up to 7 days postpartum).
Adequate treatment of syphilis was defined, according to pro-
vincial guidelines, as two or more doses of 2.4 mega units of
benzathine penicillin, and inadequate treatment was defined
as one dose or no treatment.8 13 A positive syphilis test was
defined by the on-site and/or laboratory RPR test results; par-
ticipants who were missing test results were treated based on
clinical judgment (in 33 of 7618 women, or <1%).
Sample size
The study was designed with 80% power of detecting a 50%
reduction in the incidence of perinatal death among women
with syphilis from 12% in the control clinics to 6% in the
intervention clinics. Baseline data from this trial9 showed that
syphilis prevalence was 9%, 68% of women received adequate
treatment, 19% received no treatment, and overall perinatal
mortality was 11%. To adjust for the clustering effect of the
trial design, the coefficient of variation of the syphilis
prevalence (CV = 0.28) in the Hlabisa antenatal clinics for
19968 was used as a proxy for the between clinic variation of
perinatal deaths. Using a significance level of 5% and an aver-
age clinic sample of 50 women, seven matched pairs were
required and a recruitment period of 18 months was planned.
Analysis
Data were analysed using SAS (SAS Institute, Cary, USA). The
trial’s matched pair design was accommodated through the
use of a random effects meta-analysis across clinic pairs.19 The
risk difference or mean difference in outcome variables
between the intervention and control clinics was calculated
for each pair and a weighted average was calculated across
pairs, with the weighting inversely proportional to the
variance of the individual pairs.Weighted analyses were made
necessary by imbalances between the cluster sizes across clin-
ics in different pairs, and as zero proportions were recorded
within some pairs, the risk difference was the necessary effect
measure. All data analysis was by intention to treat.
The University of Natal research ethics committee granted
ethical approval for the study. Consent to conduct the trial was
provided by the Hlabisa District Health Service.
RESULTS
Recruitment started in the seven clinic pairs between October
1998 and February 1999, and ended in all pairs in January
2000. Of 7618 women seeking antenatal care (fig 2), syphilis
results were available for 7134 (94%). Missing results were
due largely to logistical problems in conducting the on-site
test and transporting specimens to the provincial reference
laboratory (for example, broken tubes, lost specimens), and
were unlikely to be associated with syphilis serostatus.
Of the women with available test results, 793 (11.1%) were
enrolled after testing RPR positive either on site or in the
laboratory. Table 1 compares demographic characteristics and
pregnancy histories of women attending intervention and
control clinics. There was an imbalance in the numbers
recruited between the two arms of the trial because of one
very busy clinic in the intervention arm. Participants
attending intervention clinics were slightly younger and of
lower mean gravidity than those attending control clinics, but
Figure 1 Trial profile.
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there were no differences in gestational age or previous preg-
nancy loss. In adjusted analyses (not shown), the baseline dif-
ferences in age and gravidity did not alter substantially trial
findings and as a result only unadjusted results are presented
here.
Syphilis prevalence
The prevalence of laboratory confirmed syphilis was 7.5% and
was similar in intervention and control clinics after account-
ing for the matched pair design of the study. RPR titre data
were determined during the second half of the study period
only, and were available for 346 women (55%) attending
intervention clinics and 134 (75%) of those attending control
clinics. The median titre was 1:4, and 20% of participants had
titres of 1:16 or greater.
Validity of the on-site test
Of the 394 women who tested positive for syphilis in the labo-
ratory, 246 also tested positive on site (on-site test sensitivity,
62%). Of the 4320 women who tested negative in the labora-
tory, 4138 tested negative on site (on-site test specificity, 96%;
percentage agreement, 93%; κ = 0.56). The sensitivity of the
on-site test increased to 83% among womenwith titres greater
than 1:4.
Figure 2 Flow of participants at each stage of trial. Note: Numbers and percentages presented in this figure are totals for all intervention or
control clinics, and ignore the matched pair design; percentages may sum to slightly more or less than 100% because of rounding.
Table 1 Characteristics of women enrolled in the trial at intervention (on-site testing and laboratory testing) and control







Mean age (years) 25.8 27.0 −1.3 −2.4 to −0.3
Mean gestation age at booking (weeks) 23.7 24.2 −0.8 −1.7 to 0.1
Proportion primigravida 25.8% 20.7% 8.9% 1.0 to 17.3
Mean gravida‡ 3.0 3.4 −0.4 −0.7 to −0.02
Proportion reporting previous miscarriage or stillbirth 12.0% 12.5% −0.0% −10.0 to 9.6
*Differences for means and proportions are for (intervention-control), and are adjusted for cluster design based on a weighted average of the risk
difference within each clinic pair.
†CI = confidence interval.
‡Including current pregnancy.
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Syphilis treatment
The average time from the first antenatal visit to the comple-
tion of syphilis treatment was 16 days shorter for women
attending intervention clinics compared to those attending
control clinics (95% CI: 11 to 21, p<0.001). Comparing inter-
vention and control clinics (table 2), similar proportions
received no treatment (20% v 19%) and adequate treatment
(64% v 69%; adjusted risk difference, 0.3%; 95% CI: −10.4 to
10.9). At the intervention clinics, 63 of the 125 of women who
required treatment (according to laboratory test results or
clinical judgement) but received none were negative in the
on-site test (50%). In contrast with this, only 17% of women
who received at least one penicillin injection were negative in
the on-site test (86 of 493), suggesting that a negative on-site
test result was strongly associated with receiving no treatment
(adjusted risk difference, intervention minus control, 28%;
95% CI: 20 to 36).
Pregnancy outcome
Pregnancy outcome data were available for 723 women (91%).
Failure to collect outcome data was due primarily to
movement outside of the district for delivery. In this case,
women did not deliver at a facility in the district, and could
not be traced at their home. Mobility, even during pregnancy,
is very common in this setting, and this censoring is unlikely
to be related to pregnancy outcome.
Of the women with pregnancy outcome data, 12 women in
the intervention arm (2.1%) and five women in the control
arm (3.1%) reported miscarriages; these were excluded from
the perinatal mortality analysis. Table 3 shows the distribution
of outcomes among viable pregnancies, for each clinic pair and
overall. In all, 3.3% of pregnancies resulted in perinatal death
among women attending intervention clinics, compared with
5.1% among women attending control clinics (adjusted risk
difference, −0.9%; 95% CI: −4.4 to 2.7, p=0.31).
DISCUSSION
Our trial did not demonstrate a significant impact of
implementing on-site syphilis testing in addition to laboratory
testing on perinatal mortality and treatment rates, despite
substantially reducing the delay to treatment. As such, we
observed no benefit to implementing an on-site testing inter-
vention in this setting, where relatively well functioning labo-
ratory based syphilis testing services are already in place.
There are several possible reasons why our trial did not
show an effect on perinatal mortality, the primary outcome.
Firstly, the power of the trial to demonstrate the hypothesised
effect was reduced by a lower than expected frequency of
perinatal deaths in control clinics (11% at baseline v 5% dur-
ing the trial), and by there being no increase in the proportion
of women adequately treated for syphilis in the intervention
clinics (68% at baseline9 and 64% in the trial). Although our
baseline results suggested that a 50% reduction was possible,
it is important to note that less dramatic reductions in perina-
tal mortality are also of public health relevance. Secondly, the
intervention failed to treat a greater proportion of women at
intervention clinics compared to control clinics. This appears
to be due primarily to technical and logistical difficulties
around use of the on-site test, and the relatively high quality
of laboratory services provided in the control arm.
The on-site test is relatively complex, as serum needs to be
separated from cells and mixed with antigen, and reading the
result can be subjective and difficult.With high workloads and
limited staffing, nurses at busy intervention clinics frequently
Table 2 Comparison of proportion of women receiving treatment and delays to







difference (%)* 95% CI†
No (%) of women receiving
No treatment 125 (20.2) 34 (19.4) 2.2 −9.2 to 13.6
Adequate treatment‡ 396 (64.1) 120 (68.6) 0.3 −10.4 to 10.9
Intervention Control
Adjusted mean
difference (days)* 95% CI†
Mean delays to treatment (in days)
First dose 4 21 −16.3 −19.8 to −12.7
Second dose 12 30 −16.9 −21.7 to −12.1
Third dose 21 37 −16.0 −21.0 to −11.1
*Risk differences and mean differences are for (intervention-control), and are adjusted for cluster design
based on a weighted average of the risk difference within each clinic pair.
†CI = confidence interval.
‡Adequate treatment is defined as receiving two or more doses.
Table 3 Risk differences and 95% confidence intervals (CI) for pregnancy outcomes
within each matched pair, with overall measure weighted by clinic pair (stratum) size
Pair No
Perinatal deaths/total births (%)
Risk difference (%)* 95% CIIntervention Control
1 12 / 234 (5.1) 1 / 38 (2.6) 2.5 −3.3 to 8.3
2 4 / 126 (3.2) 2 / 37 (5.4) −2.2 −10.1 to 5.7
3 0 / 47 (0.0) 4 / 35 (11.4) −11.4 −22.6 to −0.02
4 1 / 44 (2.3) 1 / 28 (3.6) −1.3 −9.5 to 6.9
5 0 / 34 (0.0) 0 / 5 (0.0) 0.0 −22.5 to 22.5
6 1 / 18 (5.6) 0 / 3 (0.0) 5.6 −29.0 to 40.2
7 0 / 46 (0.0) 0 / 11 (0.0) 0.0 −11.7 to 11.7
Overall 18 / 549 (3.3) 8 / 157 (5.1) −0.9 −4.4 to 2.7
*Risk differences are for (intervention – control).
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had difficulty in conducting the on-site test, informing women
of their infection, and initiating treatment. Additional
problems were encountered in maintaining a regular supply of
testing materials, particularly reagent and batteries for
rotators. Even when test results were available, nurses
frequently told us that some women left the clinic before
receiving their results. These logistical problems in the
conduct of the on-site test echo previous experiences from
other developing country primary care settings.5 10 14 20 The
sum of these experiences suggests that the currently available
technology for on-site testing is perhaps inadequate, both in
terms of ease of use and in distinguishing weak positive
results. Qualitative serology is generally highly sensitive and
the materials used in the RPR test have been shown to be
durable.21 However, the test requires considerable time to con-
duct adequately, and considerable experience to read accu-
rately, particularly for low and moderate titres. It is not clear
whether low titre RPR results indicate a substantially
increased risk for perinatal mortality.22 However as the on-site
test showed substantially higher sensitivity in detecting
higher titre infections, it is likely that on-site testing
represents an important approach for identifying high titre
(and possible high risk) infections in settings without labora-
tory access.
Although there have been recent developments in syphilis
laboratory diagnostics, there have been few advances in the
technology of syphilis screening, particularly in tests which
may be used in resource limited primary care settings. The
difficulties we and others have encountered in on-site syphilis
screening are in stark contrast with recent advancements in
rapid HIV testing, in which the development of an inexpen-
sive, easy to use, and accurate test has led to major
improvements in the availability and feasibility of screening
for HIV in developing countries.23 Given the burden of uniden-
tified and untreated syphilis infection on both perinatal and
adult health, there is a clear need for advances in syphilis
screening technology.
In addition, the control arm in this trial received services
which may be of a relatively high quality compared to other
resource limited healthcare settings. A range of factors
contribute to the failure of laboratory based antenatal syphilis
screening programmes. These include the failure of women to
return for their test results, as well as logistical difficulties and
delays in specimen collection, transport and testing, and the
return of laboratory results. Here, on-site testing was
evaluated in a context of relatively well functioning public
sector laboratory services (at least in comparison with other
settings in sub-Saharan Africa), and the nature of trial imple-
mentation may have also contributed to improvements to the
existing mechanisms for laboratory based testing. In this
light, the failure to demonstrate the impact of on-site testing
may be attributed in part to the relatively high quality of serv-
ices provided in the control arm. As a result, our null findings
may not be generalisable to settings where laboratory services
are less functional, or altogether non-existent.
In conclusion, our trial, while somewhat underpowered,
does not support using on-site syphilis testing in addition to
laboratory based testing. However, there still is a range of set-
tings in the developing world where laboratory facilities for
antenatal syphilis testing function poorly or do not exist at
all.3 In such instances, on-site testing may represent an
important intervention to improve antenatal care and reduce
perinatal mortality.
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